Updated:
Merck KGaA
Merck KGaA traces its roots to 1668, when Friedrich Jacob Merck opened a pharmacy in Darmstadt.
Merck KGaA
Merck KGaA traces its roots to 1668, when Friedrich Jacob Merck opened a pharmacy in Darmstadt. The company remains majority-controlled by the Merck family through E. Merck KG, a limited partnership holding 70.3% of shares (per the firm, 2023). Belén Garijo took over as CEO in 2021, succeeding Matthias Zachert, and is the first woman to lead the firm. The firm operates through three divisions: Healthcare (prescription drugs for oncology, neurology, and fertility), Life Science (lab supplies and process materials under the MilliporeSigma brand), and Electronics (liquid crystals and semiconductors). In 2023, Healthcare contributed about 40% of sales, Life Science 40%, and Electronics 20% (per the firm's annual report, 2023). Geographically, Europe accounts for 23% of revenue, the Americas 29%, Asia-Pacific 41%, and other regions 7%. Merck KGaA employs roughly 64,000 people globally, with significant operations in Darmstadt, Boston, Beijing, and Tokyo. In November 2023, the company announced a €500M investment in a new Life Science R&D center in Darmstadt (per the firm, November 2023). The firm also runs a corporate venture capital arm, M Ventures, which invests in early-stage life science and tech startups. A structural differentiator: Merck KGaA is legally independent of Merck & Co. (MSD) in the US and Canada — a separation dating to the 1917 expropriation during World War I. The family's control via E. Merck KG gives the company a long-term orientation unusual for a publicly traded firm, enabling sustained R&D and capital expenditure without quarterly earnings pressure.
General information
Firm type
other
Year founded
1668
AUM
Undisclosed
Location
Region
Europe
Country
Germany
City
Darmstadt
Corporate office
Darmstadt, Germany
Additional offices
Billerica, MA, United States; Beijing, China; Tokyo, Japan; and others
Principals
Belén Garijo
Chief Executive Officer
Matthias Zachert
Chairman of the Executive Board (retired 2023)
Sector focus
Frequently asked questions
Who controls Merck KGaA?
The Merck family controls the company through E. Merck KG, a limited partnership holding 70.3% of shares (per the firm's 2023 annual report). The firm is publicly traded on the Frankfurt Stock Exchange under the ticker MRK.
How is Merck KGaA different from Merck & Co. (MSD) in the US?
Merck KGaA and Merck & Co. have been separate entities since 1917, when US authorities expropriated the American subsidiary of the German parent. Merck KGaA operates as Merck in most of the world but uses the brand EMD in the US and Canada to avoid confusion.
What are the main business segments of Merck KGaA?
Merck KGaA operates three divisions: Healthcare (prescription drugs), Life Science (lab materials and services via MilliporeSigma), and Electronics (liquid crystals, specialty chemicals for semiconductors). In 2023, Healthcare and Life Science each contributed about 40% of sales, with Electronics at 20% (per the firm's annual report, 2023).
Does Merck KGaA have a venture capital arm?
Yes, M Ventures is the corporate venture capital arm of Merck KGaA. It invests in early-stage startups in life science, healthcare, and technology, with a focus on disruptive innovation.
Where does Merck KGaA generate most of its revenue geographically?
Asia-Pacific is the largest revenue region at 41% of total sales, followed by the Americas at 29% and Europe at 23% (per the firm's 2023 annual report). Growth markets in China and the rest of Asia have been a key focus for expansion.
Is Merck KGaA primarily a pharmaceutical or a chemical company?
Merck KGaA is a diversified science and technology company. While its Healthcare division is pharma-focused, Life Science and Electronics are equally significant: the Life Science division supplies labs worldwide, and Electronics leads the global market for liquid crystals used in displays.
Who is the CEO of Merck KGaA?
Belén Garijo is the CEO, a role she assumed in 2021. She previously served as deputy CEO and head of the Healthcare division. She is the first woman to lead the company in its 350-year history (per the firm, 2021).
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: